• Genentech reported positive prespecified interim Phase III results for investigational sefaxersen in adults with primary IgA nephropathy.
• The trial met its primary endpoint, showing a meaningful reduction in protein leakage in urine versus placebo, supporting potential disease-slowing benefit.
• Interim findings will be presented at an upcoming medical meeting, with data also set to be shared with regulators.
• The study continues blinded to assess longer-term kidney function outcomes over two years.
• Safety results were consistent with prior reports, with no new safety signals identified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.